Labopharm completes $30 million bought deal financing

On May 26, 2004, Labopharm Inc. completed a bought deal offering for gross proceeds of $30 million. The major portion of the proceeds will be used for product commercialization and for the financing of scientific research and experimental development of the company's technologies. The offering was co-led by Desjardins Securities Inc. and RBC Dominion Securities Inc. with an underwriting syndicate also comprised of National Bank Financial Inc., Canaccord Capital Corporation and GMP Securities Ltd.

Labopharm was represented in-house by Lisane Dostie, general counsel and corporate secretary and by Fasken Martineau in Montreal, with a team that included Louis-François Hogue, Frédéric Boucher, Catherine Isabelle, Gabriel Castiglio and Pierre-Étienne Simard (securities, mergers and acquisitions), Gilles Carli (taxation) and Julie Gauvreau (intellectual property) from Goudreau Gage Dubuc.